Literature DB >> 16458035

Suppression of pattern-recognition receptor TLR4 sensing does not alter lung responses to pneumovirus infection.

Pedro Faisca1, Dao Bui Tran Anh, Anne Thomas, Daniel Desmecht.   

Abstract

Toll-like receptors (TLR) are an important component in the innate immune response to a wide variety of pathogens. Recently, a series of studies has addressed the hypothesis that TLR4 also participates in the host innate response against respiratory syncytial virus (RSV), the leading cause of lower respiratory tract infections in infants and young children. In most of the studies available, RSV, which is not a natural pathogen of mice, has been systematically used in mouse models of human bronchiolitis, with conflicting results. Pneumonia virus of mice (PVM), a member of the pneumovirus genus, shares many similarities with RSV. The serological and structural relationships that exist between them suggest that the immune response to these viruses may be similar in their respective natural hosts. To determine the role of TLR4 in host defense against PVM, TLR4-competent and TLR4-deficient mice were intranasally infected with PVM. Variation of body weight, pulmonary function values, histopathology, and pulmonary viral loads were analyzed. None of the investigated clinical, functional, histological and virological parameters was different between strains, which demonstrates that the sensitivity of the mouse to its natural pneumovirus infection is independent of the presence or absence of TLR4 sensing.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16458035     DOI: 10.1016/j.micinf.2005.08.010

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  9 in total

Review 1.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

2.  Lactobacillus-mediated priming of the respiratory mucosa protects against lethal pneumovirus infection.

Authors:  Stanislaw J Gabryszewski; Ofir Bachar; Kimberly D Dyer; Caroline M Percopo; Kristin E Killoran; Joseph B Domachowske; Helene F Rosenberg
Journal:  J Immunol       Date:  2010-12-17       Impact factor: 5.422

Review 3.  Human genetic factors and respiratory syncytial virus disease severity.

Authors:  Isao Miyairi; John P DeVincenzo
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

4.  TLR4 Asp299Gly and Thr399Ile polymorphisms: no impact on human immune responsiveness to LPS or respiratory syncytial virus.

Authors:  Renée N Douville; Yuriy Lissitsyn; Aaron F Hirschfeld; Allan B Becker; Anita L Kozyrskyj; Joel Liem; Nathalie Bastien; Yan Li; Rachel E Victor; Mehtab Sekhon; Stuart E Turvey; Kent T HayGlass
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

Review 5.  Understanding the mechanisms of viral induced asthma: new therapeutic directions.

Authors:  Nicole G Hansbro; Jay C Horvat; Peter A Wark; Philip M Hansbro
Journal:  Pharmacol Ther       Date:  2008-01-29       Impact factor: 12.310

Review 6.  Pneumonia virus of mice: severe respiratory infection in a natural host.

Authors:  Helene F Rosenberg; Joseph B Domachowske
Journal:  Immunol Lett       Date:  2008-04-22       Impact factor: 3.685

7.  Respiratory syncytial virus activates innate immunity through Toll-like receptor 2.

Authors:  Matthew R Murawski; Glennice N Bowen; Anna M Cerny; Larry J Anderson; Lia M Haynes; Ralph A Tripp; Evelyn A Kurt-Jones; Robert W Finberg
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

Review 8.  The Pneumonia Virus of Mice (PVM) model of acute respiratory infection.

Authors:  Kimberly D Dyer; Katia E Garcia-Crespo; Stephanie Glineur; Joseph B Domachowske; Helene F Rosenberg
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

9.  Efficient replication of pneumonia virus of mice (PVM) in a mouse macrophage cell line.

Authors:  Kimberly D Dyer; Ingrid Mm Schellens; Cynthia A Bonville; Brittany V Martin; Joseph B Domachowske; Helene F Rosenberg
Journal:  Virol J       Date:  2007-06-04       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.